An effective strategy for the targeted delivery of new antimalarials
Xavier Fernàndez Busquets’ joint IBEC-ISGlobal Nanomalaria group has moved a step closer to the validation of immunoliposomes as a vehicle for antimalarial drugs by showing that they increase the efficacy of lipohilic (poorly soluble) compounds in a mouse model of malaria.
The results, published in Biomaterials, suggest that this strategy could be used for the treatment of severe malaria.
Most antimalarial drugs currently in the pipeline are poorly soluble in water, and high amounts are needed to ensure their efficacy, particularly in cases of severe malaria.
Some research published in PLOS ONE represents a new step towards translating IBEC’s basic research – specifically the novel signal processing and interpretation algorithms developed by Raimon Jané’s group – to clinical applications in hospitals.